Itolizumab
- Generic Name
- Itolizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1116433-11-4
- Unique Ingredient Identifier
- XQQ2RHV14N
- Background
Itolizumab is under investigation in clinical trial NCT04605926 (A Study to Evaluate the Efficacy and Safety of Itolizumab in Subjects Hospitalized With COVID-19).
- Associated Conditions
- -
- Associated Therapies
- -
Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT05986162
Safety and Preliminary Clinical Activity of Itolizumab in ARDS
- First Posted Date
- 2023-08-07
- Last Posted Date
- 2023-08-07
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT05978544
Safety and Clinical Activity of Itolizumab in aGVHD
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2023-05-25
- Lead Sponsor
- Biotech Pharmaceutical Co., Ltd.
- Target Recruit Count
- 44
- Registration Number
- NCT05823675
- Locations
- 🇨🇳
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Phase 3
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Equillium
- Target Recruit Count
- 200
- Registration Number
- NCT05263999
- Locations
- 🇦🇺
Royal Melbourne Hospital, East Melbourne, Australia
🇦🇺Austin Health, Heidelberg, Australia
🇦🇺Westmead Hospital, Westmead, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath